Table 1.
Clinical characteristics of COVID-19 Patients with Neurologic Consultation for Abnormal Movements.
| Case # | Age | Sex | BMI | Comorbidities | COVID-19 Symptoms on Admission | Admit PaO2 (mm Hg) | BUN (mg/dL) | Crea. (mg/dL) | GCS | RASS | CT Brain | MRI Brain | EEG | Diagnosis | Treatment | Disposition at Discharge |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 51 | M | 30.2 | CAD | Respiratory, GI, Headache | 74 | 40 | 1.0 | 8 T | 1 | No acute findings | N/A | Generalized slowing consistent with encephalopathy | Myoclonus | Midazolam | Home |
| 2 | 77 | M | 30.7 | HTN, CKD, PVD | Respiratory, GI | 104 | 30 | 1.64 | 8 | −4 | Acute Subdural Hemorrhage | N/A | N/A | Probable Physiologic Tremor | None | Acute Inpatient Rehabilitation |
| 3 | 68 | M | 29.9 | HTN, CKD | Respiratory, Syncope | 94 | 16 | 0.8 | 3 T | −4 | Chronic Microvascular Disease | Incomplete sulcal FLAIR suppression, no acute stroke | Generalized R > L slowing consistent with encephalopathy | Myoclonus | Levetiracetam | Home (AMA) |
| 4 | 41 | M | 34.7 | None | Respiratory, GI, Anosmia, Headache | 89 | 8 | 0.68 | 3 T | −5 | No acute Findings | Subtle cortical FLAIR signal, no acute stroke | N/A | Myoclonus | Weaning of ventilator | Home |
| 5 | 54 | M | 36.9 | HTN | Respiratory | 60 | 13 | 1.25 | 3 T | −5 | No acute findings | N/A | Generalized slowing consistent with encephalopathy | Myoclonus | Levetiracetam | LTACH |
| 6 | 36 | F | 55.2 | None | Respiratory, GI, Anosmia, Dizziness | 93 | 18 | 0.61 | 15 | 0 | N/A | No acute findings | N/A | Functional Tremor | Physical and Occupational therapy | Home |
| 7 | 68 | F | 29.9 | HTN, DMII, CKD | Encephalopathy | 67 | 69 | 4.82 | 7 T | −3 | Chronic Microvascular Disease | N/A | Generalized slowing consistent with encephalopathy | Myoclonus | Renal replacement therapy | Deceased |
| 8 | 42 | M | 41.4 | None | Respiratory,GI, Headache | 89 | 49 | 2.41 | 3 T | −4 | N/A | N/A | N/A | Myoclonus | None | Deceased |
| 9 | 66 | M | 23.8 | HTN, DMII | Respiratory | 97 | 17 | 0.92 | 14 | 0 | No acute findings | Symmetrical dural enhancement | Seizure | Focal Seizures | Lorazepam, Levetiracetam, Lacosamide | Acute Inpatient Rehabilitation |
| 10 | 78 | M | 22.4 | Cancer | Respiratory | 81 | 39 | 1.46 | 10 T | −1 | N/A | N/A | N/A | Serotonin Syndrome | Discontinuation of fentanyl | Acute Inpatient Rehabilitation |
| 11 | 78 | M | 24.8 | HTN, DMII, CAD, Stroke | Respiratory | 129 | 75 | 3.5 | 9 T | 0 | Diffuse atrophy, no acute findings | N/A | N/A | Focal Seizures | Lorazepam | LTACH |
Key: M = Male, F = Female, BMI = Body Mass Index, BUN = Blood Urea Nitrogen, Crea = Creatinine, CAD = Coronary Artery Disease, HTN = Hypertension, CKD = Chronic Kidney Disease, PVD = Peripheral Vascular Disease, DMII = Diabetes Mellitus Type II, GI = Gastrointestinal, GCS = Glasgow Coma Scale, RASS = Richmond Agitation-Sedation Scale, AMA = Against Medical Advice, LTACH = Long-term Acute Care Hospital.